Marc-Antoine Bazin

Dr. Marc-Antoine Bazin

Université de Nantes, Cibles et Médicaments des Infections et du Cancer, IICiMed EA 1155, Département de Chimie Thérapeutique, F-44000 Nantes, France
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2016 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
DMDavid Montoir
David Montoir
SBSophie Barillé-Nion
Sophie Barillé-Nion
ATAlain Tonnerre
Alain Tonnerre
PJPhilippe Juin
Philippe Juin
MDMuriel Duflos
Muriel Duflos
Marc-Antoine BazinMarc-Antoine Bazin
Marc-Antoine Bazin

8 January 2014 in European Journal of Organic Chemistry
Verified
Journal Article
Closed access
PDF file
DMDavid Montoir
David Montoir
ATAlain Tonnerre
Alain Tonnerre
MDMuriel Duflos
Muriel Duflos
Marc-Antoine BazinMarc-Antoine Bazin
Marc-Antoine Bazin

1 July 2018 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
Viet Hung DaoViet Hung Dao
Viet Hung Dao
Isabelle Ourliac-GarnierIsabelle Ourliac-Garnier
Isabelle Ourliac-Garnier
Marc-Antoine BazinMarc-Antoine Bazin
Marc-Antoine Bazin
CJCatherine Jacquot
Catherine Jacquot
BBBlandine BARATTE
Blandine BARATTE
Pascal MarchandPascal Marchand
Pascal Marchand

17 November 2019 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
ACAnne Cecília Nascimento da Cruz
Anne Cecília Nascimento da Cruz
DBDalci José Brondani
Dalci José Brondani
TSTemístocles I´talo de Santana
Temístocles I´talo de Santana
LSLucas Oliveira da Silva
Lucas Oliveira da Silva
EBElizabeth Fernanda da Oliveira Borba
Elizabeth Fernanda da Oliveira Borba
TGTeresinha Gonçalves-Silva
Teresinha Gonçalves-Silva
Fourteen arylsemicarbazone derivatives were synthesized and evaluated in order to find agents with potential anticancer activity. Cytotoxic screening was performed against K562, HL-60, MOLT-4, HEp-2, NCI-H292, HT-29 and MCF-7 tumor cell lines. Compounds 3c and 4a were active against the tested cancer cell lines, being more cytotoxic for the HL-60 cell line with IC50 values of 13.08 μM and 11.38 μM, respectively. Regarding the protein kinase inhibition assay, 3c inhibited seven different kinases and 4a strongly inhibited the CK1δ/ε kinase. The studied kinases are involved in several cellular functions such as proliferation, migration, cell death and cell cycle progression. Additional analysis by flow cytometry revealed that 3c and 4a caused depolarization of the mitochondrial membrane, suggesting apoptosis mediated by the intrinsic pathway. Compound 3 c induced arrest in G1 phase of the cell cycle on HL-60 cells, and in the annexin V assay approximately 50% of cells were in apoptosis at the highest concentration tested (26 μM). Compound 4a inhibited cell cycle by accumulation of abnormal postmitotic cells at G1 phase and induced DNA fragmentation at the highest concentration (22 μM).

6 January 2025 in ChemMedChem
Verified
Journal Article
Closed access
LTLhana Tisseur
Lhana Tisseur
SCSandrine Cojean
Sandrine Cojean
KGKhadidiatou Gassama
Khadidiatou Gassama
CLcédric logé
cédric logé
FPFabrice Pagniez
Fabrice Pagniez
Pascal MarchandPascal Marchand
Pascal Marchand

30 October 2021 in Molecules
Verified
Journal Article
Open access
PDF file
Viet Hung DaoViet Hung Dao
Viet Hung Dao
Isabelle Ourliac-GarnierIsabelle Ourliac-Garnier
Isabelle Ourliac-Garnier
CLcédric logé
cédric logé
Florence McCarthyFlorence McCarthy
Florence McCarthy
Stéphane BachStéphane Bach
Stéphane Bach
Pascal MarchandPascal Marchand
Pascal Marchand
Pim kinases (proviral integration site for Moloney murine leukemia virus kinases) are overexpressed in various types of hematological malignancies and solid carcinomas, and promote cell proliferation and survival. Thus, Pim kinases are validated as targets for antitumor therapy. In this context, our combined efforts in natural product-inspired library generation and screening furnished very promising dibenzo[b,d]furan derivatives derived from cercosporamide. Among them, lead compound 44 was highlighted as a potent Pim-1/2 kinases inhibitor with an additional nanomolar IC50 value against CLK1 (cdc2-like kinases 1) and displayed a low micromolar anticancer potency towards the MV4-11 (AML) cell line, expressing high endogenous levels of Pim-1/2 kinases. The design, synthesis, structure–activity relationship, and docking studies are reported herein and supported by enzyme, cellular assays, and Galleria mellonella larvae testing for acute toxicity.